These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29741285)

  • 1. Systematic review and meta-analysis: Development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis e antigen seroconversion.
    Zhou TC; Lai X; Feng MH; Tang Y; Zhang L; Wei J
    J Viral Hepat; 2018 Oct; 25(10):1172-1179. PubMed ID: 29741285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients.
    Mak LY; To WP; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
    World J Gastroenterol; 2019 Mar; 25(11):1398-1408. PubMed ID: 30918432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.
    Hsu YS; Chien RN; Yeh CT; Sheen IS; Chiou HY; Chu CM; Liaw YF
    Hepatology; 2002 Jun; 35(6):1522-7. PubMed ID: 12029639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance.
    Liu F; Wang XW; Chen L; Hu P; Ren H; Hu HD
    Aliment Pharmacol Ther; 2016 Jun; 43(12):1253-61. PubMed ID: 27117732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma.
    To WP; Mak LY; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
    J Viral Hepat; 2019 Dec; 26(12):1473-1480. PubMed ID: 31418973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune-tolerant phase of chronic hepatitis B virus infection: A systematic review and meta-analysis.
    Liu M; Zhao T; Zhang J; Bu B; Zhang R; Xia X; Geng J
    Rev Med Virol; 2024 Jul; 34(4):e2570. PubMed ID: 38964866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
    Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What can we learn from hepatitis B virus clinical cohorts?
    Lin CL; Tseng TC; Kao JH
    Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Nikolopoulou G; Raptopoulou-Gigi M; Gogos C; Vafiadis-Zouboulis I; Karamanolis D; Chouta A; Ilias A; Drakoulis C; Mimidis K; Ketikoglou I; Manesis E; Mela M; Hatzis G; Dalekos GN;
    J Viral Hepat; 2015 Feb; 22(2):120-7. PubMed ID: 25040685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran.
    Makvandi M; Soleimani Jelodar R; Samarbafzadeh A; Neisi N; Sharifi Z; Gholampour A; Masjedizadeh A; Shayesteh A
    Asian Pac J Cancer Prev; 2018 Aug; 19(8):2125-2129. PubMed ID: 30139211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B.
    Chen YC; Chu CM; Liaw YF
    Hepatology; 2010 Feb; 51(2):435-44. PubMed ID: 19918971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence of hepatocellular carcinoma and clearance of hepatitis B surface for CHB patients in the indeterminate phase: a systematic review and meta-analysis.
    Liu M; Zhao T; Zhang Y; Zhang AM; Geng J; Xia X
    Front Cell Infect Microbiol; 2023; 13():1226755. PubMed ID: 37771696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma.
    Chu CM
    J Gastroenterol Hepatol; 2000 May; 15 Suppl():E25-30. PubMed ID: 10921378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.
    Song A; Wang X; Lu J; Jin Y; Ma L; Hu Z; Zheng Y; Shen C; Chen X
    J Viral Hepat; 2021 Apr; 28(4):601-612. PubMed ID: 33455067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice.
    Lin B; Ha NB; Liu A; Trinh HN; Nguyen HA; Nguyen KK; Ahmed A; Keeffe EB; Garcia RT; Garcia G; Nguyen MH
    J Gastroenterol Hepatol; 2013 May; 28(5):855-60. PubMed ID: 23278507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term natural history of liver disease in patients with chronic hepatitis B virus infection: an analysis using the Markov chain model.
    Tada T; Kumada T; Toyoda H; Ohisa M; Akita T; Tanaka J
    J Gastroenterol; 2018 Nov; 53(11):1196-1205. PubMed ID: 29675604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice.
    Geng M; Li Y; Gao F; Sun L; Yang X; Wang R; Chen J; Zhang Q; Wan G; Wang X
    Int J Infect Dis; 2017 Sep; 62():18-25. PubMed ID: 28669850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study.
    Bortolotti F; Guido M; Bartolacci S; Cadrobbi P; Crivellaro C; Noventa F; Morsica G; Moriondo M; Gatta A
    Hepatology; 2006 Mar; 43(3):556-62. PubMed ID: 16496323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.